Celldex Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-93.0M | $-128.5M | $-127.2M | $-118.1M | $-81.6M | $-59.1M | $-44.8M | $-2.5M |
| Depreciation & Amortization | $4.4M | $3.1M | $3.0M | $2.4M | $1.9M | $2.0M | $2.2M | $2.7M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $896.0K | $997.0K | $1.0M | $1.0M | $1.0M | $1.1M | $1.9M | $3.1M |
| Stock-Based Compensation | $12.3M | $15.3M | $12.8M | $6.9M | $4.5M | $2.3M | $2.3M | $2.8M |
| Net Cash from Operating Activities | $-99.9M | $-113.0M | $-98.9M | $-101.5M | $-67.7M | $-49.8M | $-35.7M | $-30.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.8M | $2.8M | $4.9M | $1.9M | $4.2M | $303.0K | $509.0K | $2.1M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $46.5M | $68.9M | $-50.2M | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $51.3M | $14.5M | $193.2M | — | — | — | — | — |
| Net Change in Cash | $-2.2M | $-29.6M | $44.1M | $-141.4M | $144.5M | — | — | — |
| Free Cash Flow | $-101.7M | $-115.8M | $-103.8M | $-103.5M | $-71.9M | $-50.1M | $-36.2M | $-32.5M |